João L. Carapinha/LinkedIn
Jul 2, 2026, 20:48
João L. Carapinha: How Does HYMPAVZI Simplify Hemophilia Management for Patients?
João L. Carapinha, Director at Syenza, shared on LinkedIn:
”How does HYMPAVZI simplify hemophilia management for patients?
A new weekly subcutaneous option changes care pathways forever.
FDA approval expands access for adults, adolescents, and children.
This therapy offers flexibility and reduces traditional treatment burdens.
Check out the article for more insights.”
Stay updated with Hemostasis Today.
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium
-
Jul 18, 2026, 15:18Strengthening Regional Learning for Hemophilia and Sickle Cell Disease Care – Novo Nordisk
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress
-
Jul 18, 2026, 14:50Nikola Pantic: Grateful for the People Who Made ISTH 2026 Special
-
Jul 18, 2026, 14:30Denise Rezende: Werfen Reflects on a Successful ISTH 2026 Congress